Abstract 15097: Icosapent Ethyl Reduces Potentially Atherogenic Lipid and Inflammatory Markers in High-Risk Statin-Treated Patients With Stage 3 Chronic Kidney Disease and Persistent High Triglycerides

Introduction: Patients with chronic kidney disease (CKD) have increased cardiovascular disease (CVD) risk. Atherogenic and inflammatory markers beyond LDL-C likely drive this risk, but data are lacking in this population. Icosapent ethyl (IPE) is a prescription high-purity ethyl ester of the omega-3 fatty acid eicosapentaenoic acid (EPA) approved at 4 g/day as an adjunct to diet to reduce triglycerides (TG) in adults with TG ≥500 mg/dL. Methods: The 12-week ANCHOR study randomized 702 statin-treated patients at increased CVD risk with TG 200-499 mg/dL despite LDL-C control (40-99 mg/dL). Stage 3 CKD (estimated glomerular filtration rate [eGFR] ≤60 mL/min/1.73 m2 for ≥3 months) was present in 83 patients (96% white; mean age, 68 y) at baseline. This post hoc analysis assessed ANCHOR patients with stage 3 CKD at baseline randomized to IPE 4 g/d (n=18; eGFR min, max: 24.7, 59.7 mL/min/1.73 m2) or placebo (n=35; eGFR min, max: 32.7, 59.6 mL/min/1.73 m2). Endpoints included nonparametric analyses of median per...